Revenio Group

The stock market no longer seems to care about iCare and has relegated Revenio's stock to the discount bin. We see this as an opportunity.

Revenio's valuation has fallen to a historically low level, as the industry faces concerns, especially after Zeiss's grim profit warning. We consider the concerns regarding Revenio to be exaggerated and estimate the company's earnings to be firmly on an upward trend this year.

14:40

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Revenio's Q3 earnings fell short of our overly optimistic expectations, but on the other hand, the Q4 outlook appears better than we anticipated. There have been no dramatic revisions in the outlook for the coming years, but the market is showing at least small signs of recovery.

We expect the company to achieve good revenue growth, although the weakening US dollar and uncertainty caused by US tariffs are creating difficulties.